Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1
Conditions
Interventions
SPP100
Locations
25
United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Dalton, Georgia, United States
Novartis Investigative Site
Lewiston, Idaho, United States
Novartis Investigative Site
Hattiesburg, Mississippi, United States
Novartis Investigative Site
Jackson, Mississippi, United States
Start Date
August 19, 2011
Primary Completion Date
August 3, 2017
Completion Date
August 3, 2017
Last Updated
March 19, 2019
NCT06647511
NCT07439939
NCT05746039
NCT07218029
NCT06741436
NCT07098065
Lead Sponsor
Noden Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions